Sociedad Americana de Hirudoterapia

Bahagian Pengawalan Farmaseutikal — Jabatan Perkhidmatan Farmasi

Brunei DPS · Brunei Darussalam · asia pacific

Regulatory jurisdiction profileJurisdictional reference
Unregulatednational regulator

Brunei's Pharmaceutical Services Department (Ministry of Health) — leech-specific regulatory pathway has not been independently verified by ASH; medicinal leeches fall under the general national pharmaceutical and medical device framework as appropriate.

Regulatory Profile

Agency type
national regulator
Region
asia pacific
Country
Brunei Darussalam
Leech status
unregulated
Last ASH review
2026-05-27

Relevant Regulation Codes

  • Brunei Medicines Order, 2007 and Medicines (Advertisement) Regulations, 2007
  • Brunei national medical device regulatory framework
  • ASEAN Medical Device Directive (AMDD) harmonised frameworks where applicable

Prescriber Requirements

  • Brunei Medical Board–registered physician — order required for any biomedical device application
  • Allied health professional application under physician supervision per institutional protocol

Supply Chain & GMP

Brunei DPS registration as applicable; Malay (Bahasa Melayu) and English-language labelling. Standard cold-chain conditions.

Import/Export Rules

Brunei DPS and Department of Agriculture and Agrifood clearance for live invertebrates; CITES Appendix II paperwork for Hirudo medicinalis / verbana.

Reimbursement Context

Brunei's universal government-financed health system covers most inpatient interventions; outpatient hirudotherapy is generally not separately reimbursed.

ASH Editorial Notes

Leech-specific pathway not independently verified by ASH; falls under general medical device / traditional medicine framework as appropriate. South-East Asian regulatory frameworks are progressively coordinating through the ASEAN Medical Device Directive (AMDD); whether this captures live-organism medical devices has not been independently mapped by ASH.

Related Jurisdictions

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.